These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

452 related articles for article (PubMed ID: 30150978)

  • 1. Psoriasis, Cardiovascular Events, and Biologics: Lights and Shadows.
    Caiazzo G; Fabbrocini G; Di Caprio R; Raimondo A; Scala E; Balato N; Balato A
    Front Immunol; 2018; 9():1668. PubMed ID: 30150978
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
    Sbidian E; Chaimani A; Garcia-Doval I; Doney L; Dressler C; Hua C; Hughes C; Naldi L; Afach S; Le Cleach L
    Cochrane Database Syst Rev; 2021 Apr; 4(4):CD011535. PubMed ID: 33871055
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The TNF/IL-23/IL-17 axis-Head-to-head trials comparing different biologics in psoriasis treatment.
    Ten Bergen LL; Petrovic A; Krogh Aarebrot A; Appel S
    Scand J Immunol; 2020 Oct; 92(4):e12946. PubMed ID: 32697374
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
    Sbidian E; Chaimani A; Afach S; Doney L; Dressler C; Hua C; Mazaud C; Phan C; Hughes C; Riddle D; Naldi L; Garcia-Doval I; Le Cleach L
    Cochrane Database Syst Rev; 2020 Jan; 1(1):CD011535. PubMed ID: 31917873
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
    Sbidian E; Chaimani A; Garcia-Doval I; Do G; Hua C; Mazaud C; Droitcourt C; Hughes C; Ingram JR; Naldi L; Chosidow O; Le Cleach L
    Cochrane Database Syst Rev; 2017 Dec; 12(12):CD011535. PubMed ID: 29271481
    [TBL] [Abstract][Full Text] [Related]  

  • 6. IL-17 Blockade in Psoriasis: Friend or Foe in Cardiovascular Risk?
    Torres T; Raposo I; Selores M
    Am J Clin Dermatol; 2016 Apr; 17(2):107-12. PubMed ID: 26596991
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current and emerging systemic treatment strategies for psoriasis.
    Laws PM; Young HS
    Drugs; 2012 Oct; 72(14):1867-80. PubMed ID: 22938141
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potential Immunological Links Between Psoriasis and Cardiovascular Disease.
    Sajja AP; Joshi AA; Teague HL; Dey AK; Mehta NN
    Front Immunol; 2018; 9():1234. PubMed ID: 29910818
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The concept of psoriasis as a systemic inflammation: implications for disease management.
    Reich K
    J Eur Acad Dermatol Venereol; 2012 Mar; 26 Suppl 2():3-11. PubMed ID: 22356630
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biologics that inhibit the Th17 pathway and related cytokines to treat inflammatory disorders.
    Balato A; Scala E; Balato N; Caiazzo G; Di Caprio R; Monfrecola G; Raimondo A; Lembo S; Ayala F
    Expert Opin Biol Ther; 2017 Nov; 17(11):1363-1374. PubMed ID: 28791896
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interleukin 17, inflammation, and cardiovascular risk in patients with psoriasis.
    Lockshin B; Balagula Y; Merola JF
    J Am Acad Dermatol; 2018 Aug; 79(2):345-352. PubMed ID: 29477740
    [TBL] [Abstract][Full Text] [Related]  

  • 12. From the Medical Board of the National Psoriasis Foundation: The risk of cardiovascular disease in individuals with psoriasis and the potential impact of current therapies.
    Hugh J; Van Voorhees AS; Nijhawan RI; Bagel J; Lebwohl M; Blauvelt A; Hsu S; Weinberg JM
    J Am Acad Dermatol; 2014 Jan; 70(1):168-77. PubMed ID: 24184141
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association between biologic therapies for chronic plaque psoriasis and cardiovascular events: a meta-analysis of randomized controlled trials.
    Ryan C; Leonardi CL; Krueger JG; Kimball AB; Strober BE; Gordon KB; Langley RG; de Lemos JA; Daoud Y; Blankenship D; Kazi S; Kaplan DH; Friedewald VE; Menter A
    JAMA; 2011 Aug; 306(8):864-71. PubMed ID: 21862748
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Developments in systemic immunomodulatory therapy for psoriasis.
    Berger EM; Gottlieb AB
    Curr Opin Pharmacol; 2007 Aug; 7(4):434-44. PubMed ID: 17627886
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PAPA Syndrome: Challenges in Achieving Long-Term Remission.
    Smajlović H; Prohić A
    Acta Dermatovenerol Croat; 2023 Nov; 31(2):106-109. PubMed ID: 38006373
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety of biologics in psoriasis.
    Kamata M; Tada Y
    J Dermatol; 2018 Mar; 45(3):279-286. PubMed ID: 29226369
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anticytokine Immune Therapy and Atherothrombotic Cardiovascular Risk.
    Ait-Oufella H; Libby P; Tedgui A
    Arterioscler Thromb Vasc Biol; 2019 Aug; 39(8):1510-1519. PubMed ID: 31294625
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Non-immune functions of inflammatory cytokines targeted by anti-psoriatic biologics: a review.
    Lee TL; Tsai TF
    Inflamm Res; 2022 Feb; 71(2):157-168. PubMed ID: 34981130
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Psoriasis: from Pathogenesis to Targeted Therapies.
    Conrad C; Gilliet M
    Clin Rev Allergy Immunol; 2018 Feb; 54(1):102-113. PubMed ID: 29349534
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Does treatment of psoriasis reduce the risk of cardiovascular disease?
    Churton S; Brown L; Shin TM; Korman NJ
    Drugs; 2014 Feb; 74(2):169-82. PubMed ID: 24420963
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.